OBJECTIVES: Biochemical (prostate-specific antigen) recurrence of prostate cancer after radical prostatectomy remains a major problem. Better biomarkers are needed to identify high-risk patients. DNA methylation of promoter regions leads to gene silencing in many cancers. In this study, we assessed the effect of DNA methylation on the identification of recurrent prostate cancer. METHODS: We studied the methylation status of 15 pre-specified genes using methylation-specific polymerase chain reaction on tissue samples from 151 patients with localized prostate cancer and at least 5 years of follow-up after prostatectomy. RESULTS: On multivariate logistic regression analysis, a high Gleason score and involvement of the capsule, lymph nodes, seminal vesicles, or surgical margin were associated with an increased risk of biochemical recurrence. Methylation of CDH13 by itself (odds ratio 5.50, 95% confidence interval [CI] 1.34 to 22.67; P = 0.02) or combined with methylation of ASC (odds ratio 5.64, 95% CI 1.47 to 21.7; P = 0.01) was also associated with an increased risk of biochemical recurrence. The presence of methylation of ASC and/or CDH13 yielded a sensitivity of 72.3% (95% CI 57% to 84.4%) and negative predictive value of 79% (95% CI 66.8% to 88.3%), similar to the weighted risk of recurrence (determined from the lymph node status, seminal vesicle status, surgical margin status, and postoperative Gleason score), a powerful clinicopathologic prognostic score. However, 34% (95% CI 21% to 49%) of the patients with recurrence were identified by the methylation profile of ASC and CDH13 rather than the weighted risk of recurrence. CONCLUSIONS: The results of our study have shown that methylation of CDH13 alone or combined with methylation of ASC is independently associated with an increased risk of biochemical recurrence after radical prostatectomy even considering the weighted risk of recurrence score. These findings should be validated in an independent, larger cohort of patients with prostate cancer who have undergone radical prostatectomy.
OBJECTIVES: Biochemical (prostate-specific antigen) recurrence of prostate cancer after radical prostatectomy remains a major problem. Better biomarkers are needed to identify high-risk patients. DNA methylation of promoter regions leads to gene silencing in many cancers. In this study, we assessed the effect of DNA methylation on the identification of recurrent prostate cancer. METHODS: We studied the methylation status of 15 pre-specified genes using methylation-specific polymerase chain reaction on tissue samples from 151 patients with localized prostate cancer and at least 5 years of follow-up after prostatectomy. RESULTS: On multivariate logistic regression analysis, a high Gleason score and involvement of the capsule, lymph nodes, seminal vesicles, or surgical margin were associated with an increased risk of biochemical recurrence. Methylation of CDH13 by itself (odds ratio 5.50, 95% confidence interval [CI] 1.34 to 22.67; P = 0.02) or combined with methylation of ASC (odds ratio 5.64, 95% CI 1.47 to 21.7; P = 0.01) was also associated with an increased risk of biochemical recurrence. The presence of methylation of ASC and/or CDH13 yielded a sensitivity of 72.3% (95% CI 57% to 84.4%) and negative predictive value of 79% (95% CI 66.8% to 88.3%), similar to the weighted risk of recurrence (determined from the lymph node status, seminal vesicle status, surgical margin status, and postoperative Gleason score), a powerful clinicopathologic prognostic score. However, 34% (95% CI 21% to 49%) of the patients with recurrence were identified by the methylation profile of ASC and CDH13 rather than the weighted risk of recurrence. CONCLUSIONS: The results of our study have shown that methylation of CDH13 alone or combined with methylation of ASC is independently associated with an increased risk of biochemical recurrence after radical prostatectomy even considering the weighted risk of recurrence score. These findings should be validated in an independent, larger cohort of patients with prostate cancer who have undergone radical prostatectomy.
Authors: J Masumoto; S Taniguchi; K Ayukawa; H Sarvotham; T Kishino; N Niikawa; E Hidaka; T Katsuyama; T Higuchi; J Sagara Journal: J Biol Chem Date: 1999-11-26 Impact factor: 5.157
Authors: Scott A Tomlins; Daniel R Rhodes; Sven Perner; Saravana M Dhanasekaran; Rohit Mehra; Xiao-Wei Sun; Sooryanarayana Varambally; Xuhong Cao; Joelle Tchinda; Rainer Kuefer; Charles Lee; James E Montie; Rajal B Shah; Kenneth J Pienta; Mark A Rubin; Arul M Chinnaiyan Journal: Science Date: 2005-10-28 Impact factor: 47.728
Authors: W W Roberts; E J Bergstralh; M L Blute; J M Slezak; M Carducci; M Han; J I Epstein; M A Eisenberger; P C Walsh; A W Partin Journal: Urology Date: 2001-06 Impact factor: 2.649
Authors: Riichiroh Maruyama; Shinichi Toyooka; Kiyomi O Toyooka; Arvind K Virmani; Sabine Zöchbauer-Müller; Alfredo J Farinas; John D Minna; John McConnell; Eugene P Frenkel; Adi F Gazdar Journal: Clin Cancer Res Date: 2002-02 Impact factor: 12.531
Authors: Christoph Wissmann; Peter Johannes Wild; Simone Kaiser; Stefan Roepcke; Robert Stoehr; Matthias Woenckhaus; Glen Kristiansen; Jen-Chih Hsieh; Ferdinand Hofstaedter; Arndt Hartmann; Ruth Knuechel; André Rosenthal; Christian Pilarsky Journal: J Pathol Date: 2003-10 Impact factor: 7.996
Authors: Srinivasan Yegnasubramanian; Jeanne Kowalski; Mark L Gonzalgo; Marianna Zahurak; Steven Piantadosi; Patrick C Walsh; G Steven Bova; Angelo M De Marzo; William B Isaacs; William G Nelson Journal: Cancer Res Date: 2004-03-15 Impact factor: 12.701
Authors: Shinichi Toyooka; Kiyomi O Toyooka; Kenichi Harada; Kuniharu Miyajima; Prakash Makarla; Ubaradka G Sathyanarayana; Jing Yin; Fumiaki Sato; Narayan Shivapurkar; Stephen J Meltzer; Adi F Gazdar Journal: Cancer Res Date: 2002-06-15 Impact factor: 12.701
Authors: Jacob Schwartzman; Solange Mongoue-Tchokote; Angela Gibbs; Lina Gao; Christopher L Corless; Jennifer Jin; Luai Zarour; Celestia Higano; Lawrence D True; Robert L Vessella; Beth Wilmot; Daniel Bottomly; Shannon K McWeeney; G Steven Bova; Alan W Partin; Motomi Mori; Joshi Alumkal Journal: Epigenetics Date: 2011-10-01 Impact factor: 4.528
Authors: Ilona N Holcomb; Janet M Young; Ilsa M Coleman; Keyan Salari; Douglas I Grove; Li Hsu; Lawrence D True; Martine P Roudier; Colm M Morrissey; Celestia S Higano; Peter S Nelson; Robert L Vessella; Barbara J Trask Journal: Cancer Res Date: 2009-09-22 Impact factor: 12.701
Authors: Hyunseok Kang; Theresa W Gillespie; Michael Goodman; Seth A Brodie; Mina Brandes; Maria Ribeiro; Suresh S Ramalingam; Dong M Shin; Fadlo R Khuri; Johann Christoph Brandes Journal: Cancer Date: 2014-03-24 Impact factor: 6.860